FibroGen: FDA Panel to Review Roxadustat Application July 15

 FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.

The NDA submission was supported by positive results from a global Phase 3 program encompassing more than 8,000 patients. Roxadustat is approved and launched in China and Japan for the treatment of anemia of CKD in patients on dialysis and not on dialysis.

https://www.globenewswire.com/news-release/2021/04/06/2205454/33525/en/FibroGen-Announces-FDA-Advisory-Committee-to-Review-Roxadustat-New-Drug-Application-Tentatively-Scheduled-for-July-15-2021.html